Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PUBLICATIONS - New from Theta Reports - Theta's Guide to Bioterror Defense

This article was originally published in Clinica

Executive Summary

As World War II came to a close, the United States embarked on a decades-long biological and chemical weapons development program. It was seen as the next frontier of warfare, along with nuclear weaponry. The program was carried on throughout the Cold War and paralleled the nuclear arms build-up, but had a much lower profile and markedly reduced funding. Just as with the nuclear arms race, however, the chemical-biological build-up came to a halt in the 1970s, when most western nations agreed that the prospect of a large-scale biological, chemical, or nuclear attack was too horrific to contemplate.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT065669

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel